Abate Kristin sold $38 of KPTI

Karyopharm (KPTI) submitted an sNDA to the FDA for accelerated approval of XPOVIO combined with ruxolitinib to treat myelofibrosis, based on Phase 3 SENTRY trial data. The FDA previously granted Orphan and Fast Track designations to the therapy. KPTI stock is up 3.04% in pre-market trading.

Karyopharm Therapeutics (KPTI) reported Q2 earnings, highlighting a potential FDA accelerated approval for its myelofibrosis combination therapy, while also facing a cash crunch with funds lasting only until September. The company's selinexor and ruxolitinib combination showed promising results, but a $15.8 million loan payment due soon could trigger a default if not addressed. Karyopharm is exploring financing options and strategic alternatives.

Karyopharm (KPTI) reported Q2 2026 revenue of $33.4M, down from $37.9M YoY due to expired agreements. U.S. XPOVIO revenue rose to $30.8M. Net loss was $67M, including non-cash expenses. The company faces a $15.8M debt payment in September, risking a liquidity covenant breach. Management reaffirmed full-year revenue guidance of $130M-$150M and plans to submit an sNDA for selinexor in myelofibrosis.

Karyopharm Therapeutics reported Q2 results showing a $67 million loss and cash reserves of $65.4 million. A $15.8 million loan payment is due Sept. 10, and without financing or a waiver the company says it would breach a $10.0 million liquidity covenant and could default. It is negotiating with lenders and pursuing Xpovio label expansion; Q2 Xpovio sales were $30.8 million.

Karyopharm (Nasdaq: KPTI) reported Q2 2026 revenue of $33.4M, including U.S. XPOVIO (selinexor) net product revenue of $30.8M. The company said an sNDA for selinexor plus ruxolitinib in myelofibrosis is planned for August under the Accelerated Approval pathway. It reaffirmed 2026 revenue guidance of $130M to $150M.

Karyopharm Therapeutics Inc. (KPTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission – Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Rema